Abeona Therapeutics

Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Type
Public
HQ
Dallas, US
Founded
2013
Size (employees)
6 (est)
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Financials

Abeona Therapeutics's revenue was reported to be $186 k in Q1, 2017
USD

Revenue (Q1, 2017)

186 k

Net income (Q1, 2017)

(5.2 m)

EBIT (Q1, 2017)

(5.3 m)

Market capitalization (20-Oct-2017)

765.1 m

Cash (31-Mar-2017)

63.2 m
Abeona Therapeutics's current market capitalization is $765.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 m925 k1 m889 k

Revenue growth, %

(55%)12%(15%)

R&D expense

10.7 m

General and administrative expense

13.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

208 k247 k236 k258 k285 k235 k214 k184 k186 k

R&D expense

72 k81 k73 k453 k1.6 m1.9 m3 m2.7 m2.2 m

General and administrative expense

733 k868 k795 k1.7 m4.7 m4.4 m3.7 m2.4 m3 m

Operating expense total

805 k949 k868 k2.1 m6.3 m6.2 m6.7 m5.1 m5.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

424 k11.5 m40.1 m69.1 m

Inventories

77 k315 k155 k

Current Assets

575 k11.6 m40.6 m69.4 m

PP&E

6 k4 k350 k721 k
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

299 k55 k165 k7.9 m43.3 m37.4 m34.3 m31.2 m63.2 m

Current Assets

440 k203 k244 k8.2 m43.7 m37.8 m34.6 m31.9 m63.8 m

PP&E

6 k5 k4 k11 k87 k548 k639 k748 k748 k

Goodwill

39 m32.5 m32.5 m32.5 m32.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.4 m(26.8 m)(14.5 m)(21.9 m)

Depreciation and Amortization

3 k11 k551 k825 k

Inventories

174 k77 k(287 k)160 k

Accounts Payable

(1.2 m)33 k(1.2 m)2.8 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(128 k)(12.5 m)(1.5 m)(2 m)(6.1 m)(5.5 m)(6.7 m)(2.6 m)(5.2 m)

Depreciation and Amortization

1 k1 k118 k151 k174 k181 k222 k250 k

Accounts Payable

1.1 m1.3 m1.6 m638 k968 k1 m2.1 m1.9 m1.5 m
USDY, 2017

Revenue/Employee

31 k

Financial Leverage

1.1 x
Show all financial metrics

Abeona Therapeutics Market Value History

Traffic Overview of Abeona Therapeutics

Abeona Therapeutics Online and Social Media Presence

Abeona Therapeutics Company Life and Culture

You may also be interested in